Multicellular life requires two complementary programs: cells must know when to divide (and do so correctly), and they must know when to die (and do so cleanly). The cell cycle governs the former; apoptosis governs the latter. Both are tightly regulated, both fail in cancer, and both are major targets of therapeutic intervention.
The Cell Cycle: Four Phases
The cell cycle is the sequence of events a cell undergoes to duplicate its contents and divide into two daughter cells. It has four phases:
G1 Phase (Growth 1)
The cell grows in size, synthesizes proteins and organelles, and responds to growth signals. This is the primary decision point: does the cell commit to division or exit the cycle?
The G1/S checkpoint (also called the restriction point) is the main control gate. Before passing it, the cell checks:
- Sufficient nutrients and growth factor signaling
- DNA integrity (no unrepaired damage)
- Adequate cell size
Once past the restriction point, division is committed even if growth factors are withdrawn.
S Phase (DNA Synthesis)
The entire genome is replicated. Each of the ~3 billion base pairs in a human cell is copied. Origin firing, replication fork progression, and Okazaki fragment ligation all occur here. Duration: ~8 hours in human cells.
G2 Phase (Growth 2)
The cell grows further and prepares for mitosis. The G2/M checkpoint verifies that DNA replication is complete and error-free before division proceeds.
M Phase (Mitosis)
The cell physically divides. Chromosomes condense, the mitotic spindle assembles, chromosomes are segregated to opposite poles, and the cell cleaves (cytokinesis). Duration: ~1 hour. Comprises: prophase, prometaphase, metaphase, anaphase, telophase, cytokinesis.
The spindle assembly checkpoint (SAC) within M phase verifies that every chromosome is properly attached to the spindle before chromosomes are pulled apart. A single unattached kinetochore can halt the entire cell — preventing chromosomal segregation errors.
CDKs and Cyclins: The Molecular Clock
Cell cycle transitions are driven by cyclin-dependent kinases (CDKs) — kinases that are only active when bound to their regulatory subunit, cyclins. Cyclin levels oscillate through the cell cycle; CDK levels are relatively constant.
| CDK-Cyclin complex | Phase | Key substrates |
|---|---|---|
| CDK4/6 – Cyclin D | G1 | RB (retinoblastoma protein) |
| CDK2 – Cyclin E | Late G1 → S | RB, histone H1, replication factors |
| CDK2 – Cyclin A | S phase | Replication proteins, SRC |
| CDK1 – Cyclin A/B | G2 → M | Nuclear lamins, condensins, kinetochore proteins |
The oscillating CDK activity creates a cell cycle clock — once high CDK activity is established, it tends to be self-reinforcing (positive feedback), ensuring sharp transitions rather than gradual drifts.
The RB/E2F Axis: The Restriction Point Switch
The retinoblastoma protein (RB) is a central cell cycle brake. In quiescent cells, RB is hypophosphorylated and binds E2F transcription factors, preventing them from activating S-phase genes.
When cells receive growth signals → CDK4/6-Cyclin D is activated → RB is phosphorylated → RB releases E2F → E2F activates genes required for S phase entry (Cyclin E, CDK2, DNA synthesis enzymes, etc.).
This creates a bistable switch: once CDK4/6 activity rises enough to start phosphorylating RB, released E2F activates Cyclin E/CDK2, which further phosphorylates RB, releasing more E2F — positive feedback that drives the cell past the restriction point irreversibly.
RB is mutated or functionally inactivated in virtually all cancers — either by direct mutation (retinoblastoma, lung cancer, etc.), CDK4/6 amplification, or loss of CDKN2A (which encodes the CDK4/6 inhibitor p16/INK4a).
The RB/CDK4/6 axis is now a major drug target. Three CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are approved for hormone receptor-positive, HER2-negative breast cancer. They work by blocking CDK4/6 → preventing RB phosphorylation → maintaining E2F repression → blocking S-phase entry. They are now standard of care in ER+/HER2- metastatic breast cancer, demonstrating that tumor suppressor pathway understanding directly translates to therapy.
Checkpoints: Quality Control Gates
Checkpoints are surveillance mechanisms that halt cell cycle progression when damage or errors are detected:
DNA Damage Checkpoints
If DNA is damaged (double-strand breaks, single-strand gaps, replication fork stalling):
- ATM/ATR kinases are activated
- ATM/ATR phosphorylate CHK1/CHK2 kinases
- CHK1/CHK2 phosphorylate CDC25 phosphatases → targeting them for degradation
- Without CDC25, CDK-Cyclin complexes remain inhibitory-phosphorylated → cell cycle arrest
The arrest provides time for DNA repair. If repair is successful, the checkpoint is relieved and the cycle resumes. If damage is too severe, the cell enters apoptosis.
p53: The Guardian of the Genome
TP53 (encoding p53) is the most frequently mutated gene in human cancer (~50% of all tumors). p53 is a transcription factor that responds to diverse cellular stresses:
- Activated by ATM/ATR in response to DNA damage
- Activated by oncogene activation (through ARF)
- Activated by hypoxia, ribosomal stress, oxidative stress
Activated p53 drives expression of:
- CDKN1A (p21) → CDK inhibitor → G1/S and G2/M arrest
- GADD45 → G2/M arrest
- BAX, PUMA, NOXA → pro-apoptotic proteins
- MDM2 → negative feedback (MDM2 ubiquitinates p53 for degradation)
When DNA damage is mild, p53 drives arrest and repair. When damage is severe or persistent, p53 drives apoptosis — eliminating the cell to prevent propagation of damage.
Apoptosis: Programmed Cell Death
Apoptosis is a genetically encoded cell death program that eliminates cells without triggering inflammation. It's essential for:
- Development: sculpting fingers by killing inter-digit cells; eliminating excess neurons
- Immune regulation: deleting self-reactive T cells in the thymus
- Quality control: eliminating DNA-damaged or virally infected cells
Apoptosis produces characteristic morphology: cell shrinkage, chromatin condensation, nuclear fragmentation, membrane blebbing, and formation of apoptotic bodies that are phagocytosed by neighboring cells. Unlike necrosis (uncontrolled cell rupture), apoptosis is clean — no inflammatory spill.
The Intrinsic Pathway (Mitochondrial)
Activated by internal stress: DNA damage, growth factor withdrawal, hypoxia, ER stress.
Stress signal
↓
Pro-apoptotic BCL-2 proteins activated (BAX, BAK, BIM, PUMA, NOXA)
↓ overwhelm anti-apoptotic BCL-2/BCL-XL
Mitochondrial outer membrane permeabilization (MOMP)
↓
Cytochrome c release
↓
APAF-1 + cytochrome c + dATP → Apoptosome
↓
Caspase-9 activation
↓
Executioner caspases (Caspase-3, Caspase-7)
↓
Cellular demolition: DNA fragmentation, protein cleavage, membrane changes
The Extrinsic Pathway (Death Receptor)
Activated by external death signals from immune cells:
Death ligand (FasL, TRAIL, TNF) binds Death receptor (Fas, DR4/5, TNFR1)
↓
DISC (Death-Inducing Signaling Complex) assembles
↓
Caspase-8 activation
↓
Direct caspase-3 activation (Type I cells)
OR
BID cleavage → tBID → engages intrinsic pathway (Type II cells)
BCL-2 Family: The Apoptosis Control System
The BCL-2 protein family governs the intrinsic pathway. Members fall into three groups:
Anti-apoptotic: BCL-2, BCL-XL, BCL-W, MCL-1, A1 — promote survival by binding and inhibiting pro-apoptotic members
Multi-domain pro-apoptotic: BAX, BAK — form pores in the mitochondrial membrane when activated
BH3-only proteins: BIM, PUMA, NOXA, BAD, BID — sensors of stress signals; activate BAX/BAK or neutralize anti-apoptotic proteins
The balance between pro- and anti-apoptotic BCL-2 family members determines whether a cell survives or undergoes apoptosis. Cancer cells often tip this balance by overexpressing anti-apoptotic members (BCL-2 overexpression in follicular lymphoma via t(14;18) translocation).
Venetoclax is a BH3 mimetic drug that inhibits BCL-2 — it displaces BIM and other BH3-only proteins from BCL-2, activating apoptosis. Approved for CLL, AML, and multiple myeloma, venetoclax represents the clinical validation of the BCL-2 family as a drug target.
Cancer as Cell Cycle and Apoptosis Failure
Cancer is, at its core, a disease of uncontrolled cell cycle progression and apoptosis evasion. The Hallmarks of Cancer (Hanahan and Weinberg) include:
- Sustained proliferative signaling — oncogenic KRAS, EGFR mutations; growth factor self-sufficiency
- Evasion of growth suppressors — RB pathway inactivation; loss of contact inhibition
- Resisting cell death — BCL-2 overexpression; p53 mutation; anti-apoptotic survival signals
- Enabling replicative immortality — telomerase reactivation; bypassing senescence
Nearly every cell cycle regulator we've discussed in this chapter is mutated, amplified, or functionally altered in some cancer type. The list of drugs targeting these pathways has grown dramatically in the targeted therapy era.
Cell Cycle in Bioinformatics
Cell cycle analysis appears frequently in computational biology:
Cell cycle phase inference: Single-cell RNA-seq data contains a cell cycle signal — cycling cells express specific genes in S phase (MCM2, RRM2, PCNA) and G2/M (CCNB1, CDC20, BUB1). Tools like Seurat and scran include cell cycle scoring to identify cycling cells and regress out cell cycle effects when it's a confounder in analysis.
Proliferation signatures: Bulk RNA-seq gene expression scores based on cell cycle genes (like the Ki67 pathway) predict tumor growth rates and prognosis.
Checkpoint analysis: ChIP-seq for p53 binding sites reveals the genome-wide transcriptional response to DNA damage. ATAC-seq shows how chromatin accessibility changes as cells enter/exit the cell cycle.
Understanding the cell cycle at the mechanistic level allows you to interpret these computational signals correctly — recognizing when gene expression changes reflect genuine biological responses versus cell cycle effects that need to be controlled for.